Sodium spirulan (Na-SP) is a sulfated polysaccharide isolated from the blue-green alga Spirulina platensis. Na-SP has anticoagulant and fibrinolytic properties in vitro, including activation of heparin cofactor II, enhancement of vascular endothelial cell fibrinolytic activity and stimulation of endothelial proteoglycan (PG) release. In the present study, we investigated the types of endothelial PGs whose release is stimulated by Na-SP. Na-SP stimulated the PG release in a dose-and time-dependent manner. However, heparin, dextran sulfate and hyaluronan stimulated the release of heparan sulfate PGs rather than chondroitin/dermatan sulfate PGs, whereas the release of both types of PGs was strongly stimulated by Na-SP. Sepharose CL-6B chromatography of [ 35 S]sulfate-labeled PGs showed that PGs were partially released after partial degradation of the core proteins without a change in chain length of the glycosaminoglycan chains after Na-SP treatment. On the other hand, SDS-polyacrylamide gel electrophoresis and Western blot analysis of the PG core proteins indicated that the Na-SP-releasable PGs are both a large heparan sulfate PG, perlecan, and a small chondroitin/dermatan sulfate PG, biglycan, without change in the size of the core proteins. Taken together, these results suggest that Na-SP stimulates the endothelial release of both perlecan and biglycan with the intact structures, possibly by mechanisms different from those of heparin, dextran sulfate and hyaluronan; a part of the PG core proteins may be degraded after Na-SP treatment. Since perlecan and biglycan have antithrombin activities, the present data support the hypothesis that Na-SP may enhance local anticoagulant activity in the liquid phase on the endothelium via stimulation of endothelial PG release.
Proteoglycans (PGs) are macromolecules that are composed of a core protein and one or more glycosaminoglycan (GAGs) side chains in a common feature. 1) In the vascular tissue, PGs are involved in the regulation of vascular properties such as permeability, lipid metabolism, hemostasis, thrombosis, and extracellular matrix assembly. [2] [3] [4] [5] In addition, PGs influence the regulation of vascular endothelial and smooth muscle cell function mediated by growth factors 6) and cytokines. 7) There are two types of PGs classified by the structure of GAG chains: one is heparan sulfate PGs (HSPGs) and the other is chondroitin/dermatan sulfate PGs (CS/DS PGs). Vascular endothelial cells predominantly synthesize and secrete a large HSPG, perlecan, 8) and a small CS/DS PG, biglycan. 9) Perlecan exhibits antithrombin activity through the activation of antithrombin III 10) by heparin-like sequences in the heparan sulfate chains. 11) On the other hand, the antithrombin activity of biglycan is achieved by the activation of heparin cofactor II by the dermatan sulfate chains. 12) It is therefore suggested that PGs synthesized and secreted by vascular endothelial cells contribute to local anticoagulant activity on the endothelium.
Sodium spirulan (Na-SP) is a sulfated polysaccharide isolated as an antiviral agent from a hot water extract of the blue-green alga Spirulina platensis. 13, 14) On the other hand, Na-SP exhibits antithrombin activity in vitro in a fashion different from heparin, 15) suggesting that Na-SP may be an agent that can control anticoagulant activity in the blood. In addition, we found that Na-SP enhances the fibrinolytic activity of the cells through inhibition of plasminogen activator inhibitor-1 secretion. 16) This indicates that Na-SP can modu-late the anticoagulant and fibrinolytic properties of vascular endothelial cells. We hypothesized that Na-SP may influence the metabolism of endothelial PGs, since heparin has a stimulatory effect on the release of PGs from vascular endothelial cells. 17) It was shown that Na-SP stimulates the endothelial PG release as does heparin 18) ; the stimulatory effect requires both the sulfate group and a sodium ion. 19) However, the type(s) of endothelial PGs whose release is stimulated by Na-SP has not been identified yet. In the present study, we suggest that Na-SP-releasable PGs in vascular endothelial cells are both perlecan and biglycan with the intact structure, although the core proteins may be partially degraded.
MATERIALS AND METHODS

Materials
Vascular endothelial cells derived from bovine aorta were purchased from Dainippon Pharmaceutical (Osaka, Japan). Na-SP was purified as described previously. 1, 2) Dulbecco's modified Eagle's medium and fetal bovine serum were from Nissui Pharmaceutical (Tokyo, Japan) and Equitech-Bio (Kerrville, TX, U.S.A.), respectively. ASF 301 medium was from Ajinomoto (Tokyo, Japan); tissue culture dishes and plates were from Asahi Technoglass (Chiba, Japan). [ 35 were from Seikagaku (Tokyo, Japan); dextran sulfate (M r ca. 10000) and sodium dodecyl sulfate (SDS) were from Wako Pure Chemical (Osaka, Japan); Sepharose CL-6B, PD-10 columns, ECL Western blotting detection reagents, horseradish peroxidaselinked protein A, nitrocellulose membranes (Hybond ECL) and Hyper film ECL were from Amersham Biosciences (Piscataway, NJ, U.S.A.); rabbit antisera against perlecan core protein (EY-9) was a gift from Dr. John Hassell (Shriners Hospital for Children, Tampa, FL, U.S.A.); rabbit antisera against biglycan core protein (LF-96) was kindly provided by Dr. Larry Fisher (NIDR, National Institute of Health, Bethesda, MD, U.S.A.); cetylpyridinium chloride (CPC) and other reagents were from Nacalai Tesque (Kyoto, Japan).
Release of [ 35 S]Sulfate-Labeled PGs from Vascular Endothelial Cell Layers
Vascular endothelial cells were cultured in 24-well plates in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37°C in a humid atmosphere of 5% CO 2 in air until confluent, and then metabolically labeled with [ 35 S]sulfate (1 MBq/ml) for 24 h in fresh medium. After labeling, the medium was discarded and the cell layer was washed twice with serum-free ASF 301 medium. The cell layer was incubated at 37°C for 0.5, 1 or 2 h with Na-SP, heparin, dextran sulfate or hyaluronan (2.5, 5, 10 or 25 mg/ml) in fresh ASF 301 medium without [ 35 S]sulfate. After incubation, the conditioned medium was harvested and solid urea was added to a concentration of 8 M. The cell layer was washed twice with ice-cold Ca ϩ , Mg ϩ -free phosphate-buffered saline and extracted with 8 M urea solution containing 0.1 M 6-aminohexanoic acid, 5 mM EDTA, 0.1 M phenylmethansulfonyl fluoride, 0.1 M NaCl, 50 mM Tris base and 2% Triton X-100 (pH 7.5) at 4°C for 15 min, and was then harvested by scraping with a rubber policeman. The [ 35 S]sulfate-labeled PGs were treated with or without 1.7% nitrous acid in 10% acetic acid for 90 min, and evaluated by the CPC precipitation method. 20) Briefly, portions of the medium and cell layer extracts were spotted on filter papers and washed five times for 1 h in 1% CPC with 0.05 M NaCl. The radioactivity of precipitated PGs on dried filter paper was measured by liquid scintillation counting. PGs that are sensitive and resistant to treatment with nitrous acid are regarded as HSPGs and CS/DS PGs, respectively. The percentage of PG release was calculated by dividing the radioactivity in the conditioned medium by that found in both the conditioned medium and the cell layer.
Sepharose CL-6B Chromatography [ 35 S]Sulfate-labeled PGs released into the medium from vascular endothelial cell layers treated with Na-SP (10 mg/ml) for 2 h was extracted under a dissociative condition in the presence of 8 M urea. After the removal of low molecular materials (Ͻ3 kDa) with PD-10 columns equilibrated in 8 M urea buffer (pH 7.5) containing 2 mM EDTA, 1 M NaCl, 0.5% Triton X-100 and 50 mM Tris base, the macromolecules were concentrated by application to DEAE-Sephacel minicolumns (0.3 ml of resin) equilibrated in 8 M urea buffer containing 0.25 M NaCl and eluting bound radioactivity with sequential washes of 8 M urea buffer containing 3 M NaCl. The concentrated PGs were precipitated with 3.5 volumes of 1.3% potassium acetate in 95% ethanol and 80 mg/ml carrier chondroitin sulfate for 2 h at Ϫ20°C; the precipitation was repeated three times. The precipitated PGs were digested with or without 10 mg of papain in 0.1 M acetate buffer (pH 7.0) containing 5 mM EDTA and 5 mM cysteine at 65°C for 4 h. The digested samples were chromatographed on a Sepharose CL-6B column (0.9ϫ80 cm) in Tris-HCl buffer (pH 7.0) with 0.2 M NaCl. The void volume and the total volume were estimated by the elution position of dextran blue and phenol red, respectively.
Analysis of PG Core Proteins Confluent cultures of vascular endothelial cells labeled with Tran 35 S-label reagent (2 MBq/ml in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum) were incubated at 37°C for 2 h in 6 ml of fresh ASF 301 medium with Na-SP (10 mg/ml) in the absence of Tran 35 S-label reagent in 100mm dishes. After incubation, radiolabeled PGs accumulated in the conditioned medium were extracted under a dissociative condition in the presence of 8 M urea. The extract was concentrated with DEAE-Sephacel minicolumns (0.3 ml of resin) and precipitated with 1.3% potassium acetate in 95% ethanol. The precipitated PGs were digested with both heparinase I (27.6 U/ml) and heparinase II (13.8 U/ml) or with chondroitin ABC lyase (1.67 U/ml), and SDS-polyacrylamide gel electrophoresis was performed according to the procedure of Laemmli 21) on an acrylamide 4-12% gradient slab gel with a 3% stacking gel. The radiolabeled PG core proteins were visualized by autoradiography of dried gel exposed to Kodak XAR-2 film at Ϫ70°C. Estimates of core protein size were made by comparison of the migration distance of the core protein bands on the gel with a calibration curve of log MW versus the migration distance of standard protein bands. Myosin (216 kDa), b-galactosidase (129 kDa), bovine serum albumin (91 kDa), carbonic anhydrase (43.2 kDa), soybean trypsin inhibitor (33 kDa), and lysozyme (18.8 kDa) were used as standard proteins. For Western blot analysis, the SDS-polyacrylamide gel was equilibrated in 25 mM Tris transfer buffer (pH 9.5) with 20% methanol, then transferred to a nitrocellulose membrane for 90 min with a semidry transfer apparatus (Atoo, AE-6677). The membrane was blocked and exposed to a primary antibody against perlecan (EY-9, diluted 1 : 1000) or biglycan (LF-96, diluted 1 : 1000) overnight at 4°C. After incubation with horseradish peroxidase-linked protein A, bands that bound to the primary antibody were visualized by an enzyme-linked chemoluminescence procedure on Hyperfilm ECL.
Statistical Analysis Data on the release of [ 35 S]sulfatelabeled PGs were analyzed for statistical significance by oneway analysis of variance and Bonferroni's multiple t-test. p-Values of less than 0.05 were considered to indicate statistically significant differences. Figure 1 shows the effect of Na-SP on the release of [ 35 S]sulfate-labeled PGs from vascular endothelial cell layers. It was shown that Na-SP at 2.5 mg/ml and more significantly increased the PG release after a 1-h incubation; in addition, the stimulation of endothelial PG release by Na-SP at 10 mg/ml occurred after 0.5 h and longer, confirming that the stimulatory effect of Na-SP occurs in a dose-and time-dependent manner.
RESULTS
Our previous study showed that Na-SP stimulates the release of both HSPGs and CS/DS PGs when analyzed by DEAE-Sephacel ion exchange chromatography. 18) Although not only Na-SP but also other particular polysaccharides such as heparin, dextran sulfate and hyaluronan can stimulate endothelial PG release, 19) it has been unclear whether these polysaccharides act on the release of both HSPGs and CS/DS PGs, as does Na-SP. As shown in Fig. 2 , Na-SP was a particular polysaccharide with respect to endothelial PG release. Specifically, the release of CS/DS PGs, as well as that of HSPGs, was potently stimulated by Na-SP. Dextran sulfate also strongly stimulated the HSPG release but failed to exhibit such an effect on the CS/DS PG release. In the tested polysaccharides, only Na-SP potently stimulated both the CS/DS PGs release and HSPG release.
To examine whether PGs release by Na-SP is due to a degradation of core proteins and/or GAG chains by activation of some enzymatic digestion, the GAG chain size and the binding of GAGs to the core proteins were investigated by Sepahrose CL-6B chromatography (Fig. 3 ). In the control culture, most of the radiolabeled GAGs were eluted near the void volume before digestion, and the peak was shifted to K av of 0.43 after digestion with papain, suggesting that vascular endothelial cells release GAGs as PGs, and that the GAG chain size is approximately M r ca. 30000. 22) On the other hand, in Na-SP-treated culture, the radioactivity of GAGs was eluted near the void volume and at K av of 0.35. After pa- pain digestion, the radioactivity became a single peak at K av of 0.44 in both the control and Na-SP treatment group, suggesting that the GAG chain size was unchanged, but a portion of the released PGs was degraded after treatment with Na-SP. In other words, the major part of PGs released from Na-SP-treated cell layers maintained an intact structure, although a portion of the core proteins might be partially digested with certain enzyme(s) activated by Na-SP.
To assess the size of core proteins of PGs released into the medium from vascular endothelial cell layers treated with Na-SP, PGs were labeled with 35 S-labeled amino acids and separated by SDS-polyacrylamide gel electrophoresis. As shown in Fig. 4 , digestion with heparinase II/III generated a single band of HSPG core proteins at approximately 400 kDa that increased in Na-SP-treated culture. The band was immunoreactive with antisera to perlecan core protein, indicating that Na-SP stimulates the release of endothelial perlecan without degradation of the core protein. In addition, digestion with chondroitin ABC lyase generated CS/DS PG core proteins at approximately 550, 520, 250, 129 and 50 kDa; however, only the 50-kDa CS/DS PG core protein was increased by Na-SP. The small CS/DS PG core protein was immunostained with antisera to biglycan core protein, suggesting that Na-SP stimulates the release not only of perlecan but also biglycan with intact core proteins from vascular endothelial cell layers. Degradation products of perlecan and biglycan core proteins were not recognized, probably due to the small quantity, although Na-SP may induce the degradation of endothelial PGs, as shown in Fig. 3 .
DISCUSSION
Vascular endothelial cells express not only perlecan 8) and biglycan 9) but also members of the syndecan family of transmembrane PGs 23, 24) and the cell surface-associated PG, glypican-1. 23) The cells also synthesize the large aggregating chondroitin sulfate PG, versican. 25) In addition, the expression of another small leucine-rich CS/DS PG, decorin, is induced under certain conditions, for example, during the formation of neovessels [26] [27] [28] and after exposure to connective tissue growth factor 29) or interleukins. 30) However, the predominant PGs constitutively synthesized by endothelial cells are perlecan and biglycan, with a very small amount of other PGs. 9, 31) Since perlecan and biglycan synthesized by vascular endothelial cells have antithrombin activities, 10, 12) it has been postulated that the release of the PGs from endothelial cell layers may contribute to the local anticoagulant activity on vascular endothelium. In the present study, it was confirmed that Na-SP stimulates the release of both perlecan and biglycan from endothelial cell layers in a dose-and time-dependent manner. In addition, it was indicated that the majority of the perlecan and biglycan retained an intact size of the core proteins and the GAG chains. These results support the hypothesis that Na-SP exhibits an anticoagulant activity through modulation of vascular endothelial cell functions such as PG metabolism. 18) Not only Na-SP, but also heparin, dextran sulfate and hyaluronan, stimulates the release of PGs from vascular endothelial cell layers. 19) However, it was shown that the stimulation by heparin, dextran sulfate and hyaluronan occurred mainly in the HSPG release, whereas that by Na-SP did in both HSPGs and CS/DS PGs. In other words, Na-SP is a particular polysaccharide that strongly stimulates the release of CS/DS PG, specifically biglycan, from vascular endothelial cell layers. This difference suggests that Na-SP may interact with the cells and/or their extracellular matrix in a fashion different from that of heparin, dextran sulfate and hyaluronan. In addition, the present results suggest two possible mechanisms by which Na-SP exhibits anticoagulant activity in the liquid phase on the vascular endothelium. One is the direct activation of heparin cofactor II 15, 32) in the blood, and the other is the indirect activation of antithrombin III and heparin cofactor II by promotion of endothelial perlecan and biglycan release.
Regulation of the metabolism of endothelial PG has been incompletely understood. The release of PGs from vascular endothelial cell layers is stimulated by thrombin, 33) plasmin, 34) and heparin, 17) although the mechanism and the structure of released PGs have been unclear. On the other hand, we reported that stimulation of endothelial HSPG and CS/DS PG release can be mediated by the protein kinase C pathway. 35) Possible mechanisms for Na-SP stimulation of endothelial PG release are as follows: (a) Na-SP activates some proteinase(s) that can digest perlecan and/or biglycan 36) core proteins. (b) Na-SP activates some receptor(s) for polysaccharides, such as CD44 37) that activates the protein kinase C pathway. 38) (c) Na-SP loosens the extracellular matrix assembly. Degradation of a portion of core proteins after Na-SP treatment was observed in Sepharose CL-6B chromatography, suggesting that the mechanisms for Na-SP stimulation of endothelial PG release include the activation of some proteinase(s). However, no enzyme that digests perlecan and/or biglycan cores has been identified. Although it has also been unclear whether vascular endothelial cells have a receptor for Na-SP, which activates the protein kinase C pathway, the stimulation of endothelial PG release by hyaluronan may imply the involvement of CD44 in the stimulation of en- Fig. 4 . SDS-Polyacrylamide Gel Electrophoresis and Western Blot Analysis of 35 S-Labeled Amino Acids-labeled PG Core Proteins Released into the Medium from Vascular Endothelial Cell Layers after Treatment with Na-SP Confluent cultures of bovine aortic endothelial cells were labeled with 35 S-labeled amino acids and then incubated at 37°C for 2 h with Na-SP at 10 mg/ml in the absence of 35 S-labeled amino acids. The PGs were digested with or without heparinase I/II or chondroitin ABC lyase and run on a 4-12% gradient slab gel. Separately, heparinase I/II-and chondroitin ABC-generated core proteins of approximately 400 kDa and 50 kDa, respectively, were probed with an antibody specific for perlecan and biglycan. dothelial PG release by Na-SP. On the other hand, it is likely that the Na-SP stimulation may result from looseness of the extracellular matrix assembly, since most of the released PGs had intact core proteins and GAG chain size. We speculate that the mechanism by which Na-SP stimulates endothelial PG release is not simple, but includes plural ones as stated above, although the detail is unknown.
In the present study, it was demonstrated that Na-SP-releasable endothelial PGs are both perlecan and biglycan, with an intact size of GAG chains, although a portion of the PG core proteins may be degraded. The results support the hypothesis that Na-SP enhances the local anticoagulant activity in the liquid phase on the endothelium by two mechanisms: one is direct activation of heparin cofactor II 15, 23) and the other is the promotion of the endothelial release of perlecan and biglycan that can activate antithrombin III 10) and heparin cofactor II, 12) respectively. Na-SP may be a beneficial agent for the prevention of atherosclerosis because of these anticoagulant properties of Na-SP, in addition to the enhancement of endothelial fibrinolytic activity 16) and the inhibition of vascular smooth muscle cell proliferation. 39) 
